Fidelis Capital Partners LLC Purchases New Position in Humana Inc. (NYSE:HUM)

Fidelis Capital Partners LLC purchased a new position in Humana Inc. (NYSE:HUM) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 885 shares of the insurance provider’s stock, valued at approximately $225,000.

A number of other hedge funds also recently bought and sold shares of HUM. Pinnacle Wealth Management Advisory Group LLC increased its position in shares of Humana by 3.6% in the fourth quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider’s stock valued at $272,000 after buying an additional 37 shares in the last quarter. Atlas Brown Inc. grew its stake in Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after acquiring an additional 38 shares during the period. Moors & Cabot Inc. increased its holdings in Humana by 2.5% in the 3rd quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after acquiring an additional 40 shares in the last quarter. Mather Group LLC. raised its position in shares of Humana by 21.0% during the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider’s stock worth $60,000 after purchasing an additional 41 shares during the last quarter. Finally, Capital Advisors Ltd. LLC raised its position in Humana by 26.1% in the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider’s stock valued at $53,000 after purchasing an additional 43 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Analyst Ratings Changes

HUM has been the subject of a number of research reports. Truist Financial lifted their price objective on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Bank of America raised Humana from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Barclays boosted their price target on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Piper Sandler raised their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Finally, JPMorgan Chase & Co. cut their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Twenty research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $285.68.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.32% of the stock is currently owned by insiders.

Humana Trading Up 0.8 %

NYSE:HUM opened at $263.74 on Wednesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The stock has a market cap of $31.82 billion, a P/E ratio of 26.51, a P/E/G ratio of 2.05 and a beta of 0.57. The stock has a 50-day simple moving average of $271.40 and a 200-day simple moving average of $285.08.

Humana (NYSE:HUM) last announced its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a yield of 1.34%. Humana’s dividend payout ratio (DPR) is presently 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.